Abstract 200P
Background
Although third-generation EGFR-TKI is standard of care for patients with EGFR-mutant NSCLC, little is known about the predictors of response or resistance.
Methods
Here, we integrated single-cell RNA (scRNA) sequencing, bulk RNA sequencing, multiplexed immunofluorescence and flow cytometry data from pretreatment and post-resistant tumor samples of EGFR-mutant NSCLC patients received third-generation EGFR-TKIs.
Results
We show that resistant samples had a markedly enriched CXCR1+ neutrophils infiltration (P<0.01) than pretreatment samples, which were distinguished from other subtypes of neutrophils and displayed immunsupressive characteristics. Spatial analysis showed that increased CXCR1+ neutrophils predominantly infiltrated into the tumor core in resistant samples and the average distance of neutrophils to tumor cells markedly reduced from 33 to 19 μm. Deep analysis of scRNA and bulk RNA sequencing data revealed the increased interactions between CXCR1+ neutrophils and tumor cells and activated TNF-α/NF-κB signaling pathway in tumor cells of resistant samples. In vitro and in vivo experiments validated that CXCR1+ neutrophils resulted in resistance to third-generation EGFR-TKI via activating TNF-α/NF-κB signaling pathway in tumor cells. Importantly, patients with low pretreatment CXCR1+ neutrophil infiltration abundance had a dramatically longer progression-free survival (11.8 vs. 7.5 months; P=0.019) and overall survival (33.0 vs. 23.5 months; P=0.029) than those with high infiltration abundance.
Conclusions
In summary, the current findings suggest that CXCR1+ neutrophil infiltration in pretreatment tumor tissues was associated with the efficacy of third-generation EGFR-TKI and increased CXCR1+ neutrophil infiltration in posttreatment tumor tissues played a role in mediating the resistance to third-generation EGFR-TKI in EGFR-mutant NSCLC patients, underscoring the clinical significance of CXCR1+ neutrophils within the tumor microenvironment. Our findings may aid in identifying patients more likely to benefit from third-generation EGFR-TKI treatment.
Legal entity responsible for the study
The authors.
Funding
This study was supported in part by grants from the National Natural Science Foundation of China (No. 82102859, 82272875 and 12126605).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
184P - Alterations in tumorigenicity and immunogenicity of bladder cancer cells after somatic cell reprogramming
Presenter: Banu Iskender Izgi
Session: Poster Display session
185P - Characterizing the metabolic reprogramming of mutant ß-catenin in hepatocellular carcinoma
Presenter: Nathalie Wong
Session: Poster Display session
186P - Unveil and overcome PD(L)1 antibody resistance via functional genomics and clinical derived biopsies
Presenter: BIN XIE
Session: Poster Display session
187P - Single-cell RNA sequencing elucidates the role of intercommunication between epithelial cells, immune cells, and fibroblasts in high-grade serous ovarian cancer
Presenter: Xiaoting Zhao
Session: Poster Display session
Resources:
Abstract
188P - Single-cell and spatial transcriptomics delineate the microstructure and immune landscape of intrahepatic cholangiocarcinoma in the leading-edge area
Presenter: Zuyin li
Session: Poster Display session
189P - Image-guided labeling of live cells in tertiary lymphoid structures for single-cell transcriptomics
Presenter: Mengrui Cao
Session: Poster Display session
190P - Ex vivo modeling of precision immuno-oncology responses in lung cancer
Presenter: Bassel Alsaed
Session: Poster Display session
191P - Patient-derived 3D-bioprinted tumours as a relevant and innovative tool for immunotherapeutic testing.
Presenter: Kamila Pawlicka
Session: Poster Display session
192P - A new neuroendocrine model and in vitro effect of melatonin and serotonin on the PD-L1 ligand and its immunomodulatory action
Presenter: Dulce Caraveo Gutiérrez
Session: Poster Display session
193P - Humanized mice applying CD47; Prkcd; IL2rg triple KO mice exhibit enhanced human immune cell engraftment and reduced GvHD symptoms
Presenter: Seung-Ho Heo
Session: Poster Display session